Initial Treatment Recommendations for Hemophagocytic Lymphohistiocytosis (HLH) in Adults

1. Standard Initial Regimen (HLH‑94 Protocol)

The 2019 Blood guideline panel recommends initiating therapy with dexamethasone 10 mg/m² plus etoposide 150 mg/m² administered twice weekly; in adults the etoposide dose may be reduced to 50–100 mg/m² once weekly based on disease severity and organ function. [1][2]

Immediate administration of etoposide is required, together with dexamethasone 10 mg/m², to avoid delay in critically ill patients. [1][2]

Start pulsed corticosteroids (dexamethasone 10 mg/m² or prednisolone 1–2 mg/kg).
Add a modified‑dose etoposide regimen guided by clinical judgment and organ‑function assessment.
Consider adjunctive IVIG up to 1.6 g/kg divided over 2–3 days, although its benefit remains uncertain. [1][2][3][4]

A conservative approach using corticosteroids alone (with or without IVIG) may be sufficient.
Some infection‑triggered HLH cases resolve after eradication of the underlying pathogen without HLH‑specific therapy.
Weekly reassessment is essential to decide whether escalation to etoposide is needed. [4][1]5

Reduce frequency from twice weekly to once weekly and lower the dose to 50–100 mg/m² in adult patients. [6][7]
Mandatory dose reduction is required when renal function is impaired, as etoposide is primarily renally cleared. [1][2]3
No dose reduction is necessary for isolated hyperbilirubinemia or elevated transaminases. [1][2]3
Keep the cumulative etoposide exposure below 2–3 g/m² to limit toxicity, especially in non‑malignant HLH. [8][7]

Dexamethasone 10 mg/m² remains the standard choice per the HLH‑94 protocol. [1][2]3
Alternatives include prednisolone 1–2 mg/kg or a lower dexamethasone dose of 5–10 mg/m² when clinically appropriate. [2][4]3

Secondary HLH typically requires 8 weeks of etoposide therapy. [1][4]
Weekly evaluation of the need for continued etoposide is recommended rather than automatic continuation. [1][4]
Patients with residual disease after 8 weeks may benefit from maintenance therapy and, when indicated, allogeneic stem‑cell transplantation.
For those proceeding to allo‑SCT due to underlying genetic mutations, HLH‑94 maintenance therapy is advised after the initial 8‑week course. [1][4]

Broad prophylaxis against Pneumocystis jirovecii and invasive fungi is mandatory for all patients receiving HLH‑directed therapy. [1][2]5
Antiviral prophylaxis is also recommended because of profound T‑cell depletion caused by the treatment regimen. [1][2]5
Hospitalization in units equipped with HEPA‑filtered air is advised to reduce opportunistic infection risk. [1][2]5

Distinguish “malignancy‑triggered HLH” (requiring full HLH‑94 protocol) from HLH occurring during chemotherapy (often infection‑related); the latter is managed with steroids ± IVIG and etoposide is used sparingly to preserve marrow recovery. [2][4][3][1]

Rapid clinical deterioration in treatment‑naïve EBV‑infected patients mandates immediate etoposide without delay.
In less severe EBV‑HLH, a short course of corticosteroids (with or without IVIG) may be sufficient. 4

If steroids alone are inadequate, adding interleukin‑1 inhibition (anakinra) and/or cyclosporine A is suggested; anakinra has been shown to reduce mortality in sepsis patients with MAS features. [1][4]

Do not postpone treatment while awaiting complete diagnostic confirmation when clinical suspicion is high and organ dysfunction is present. [1][5]
Do not continue full‑dose etoposide without weekly reassessment of efficacy and toxicity. [1][4]
Do not apply standard pediatric dosing to adults without adjusting for comorbidities and renal function. [6][7]
Always identify and treat the underlying trigger concurrently with immunosuppressive therapy. [1][5]
Cyclosporine A can be substituted by tacrolimus, but both require therapeutic drug monitoring and toxicity surveillance. [1][4]

The HLH‑94 protocol remains the recommended standard of care; the newer HLH‑2004 protocol showed a non‑significant trend toward improved pre‑SCT mortality with upfront cyclosporine A (27 % → 19 %, P = 0.064).
The 2019 Blood guidelines constitute the most authoritative consensus for adult HLH management, emphasizing that treatment must be individualized according to the underlying condition, trigger, disease severity, and genetic background. [8][6][7][1‑7]